New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta ® in ZUMA-1 Trial
December 5, 2020, 9:00 pm
Kite, a Gilead Company (Nasdaq: GILD), today announced four-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) i
